Xbryk (Denosumab-Dssb) for Myeloma

Overview
Xbryk (denosumab-dssb) is approved by the U.S. Food and Drug Administration (FDA) to help prevent skeletal-related events in people with multiple myeloma or bone metastases from solid tumors. These events can include bone fractures, spinal cord compression, and the need for radiation or surgery due to bone damage.

Xbryk is a biosimilar to Xgeva (denosumab), meaning it is highly similar to the original FDA-approved drug with no significant differences in safety, purity, or effectiveness. It is also known by its drug name, denosumab-dssb.

This medication is a RANK ligand (RANKL) inhibitor, which means it blocks a protein that plays a key role in bone breakdown. By targeting RANKL, Xbryk helps slow down bone loss and maintain bone strength in people with multiple myeloma.

How do I take it?
Prescribing information states that Xbryk is given as a subcutaneous (under the skin) injection in the upper arm, upper thigh, or abdomen (stomach area). For multiple myeloma, the recommended dosing schedule is every four weeks. People taking this medication may also need calcium and vitamin D supplementation to prevent low calcium levels. Xbryk should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Xbryk include diarrhea, nausea, anemia (low red blood cell count), back pain, thrombocytopenia (low platelet count), peripheral edema (swelling in the limbs), hypocalcemia (low calcium levels), upper respiratory tract infections, rash, and headache.

Rare but serious side effects may include severe symptomatic hypocalcemia, osteonecrosis of the jaw (bone tissue death in the jaw), atypical femoral fractures (unusual thigh bone fractures), multiple vertebral fractures after stopping treatment, severe allergic reactions, and embryo-fetal toxicity (harm to an unborn baby). 

For more information about this treatment, visit:

Denosumab-Dssb — Samsung Bioepis 

FDA Approves Xbryk — Drugs.com